Browsing Tag
RAPT Therapeutics
2 posts
GSK trades near 2,027p as Q1 core EPS rises 9%, full-year 2026 guidance reaffirmed
GSK beat the top line and held guidance, but the harder question is whether Specialty Medicines can keep outrunning the Vaccines and General Medicines drag.
GSK to acquire RAPT Therapeutics in strategic push into long-acting food allergy biologics
GSK to acquire RAPT Therapeutics for $2.2B, targeting food allergy breakthroughs with ozureprubart. Find out how this changes its immunology strategy.